Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emerfetamab
- Development stage
- Discontinued
- Lead developer
- Amgen
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Emerfetamab is a bispecific T-cell engager (BiTE) antibody construct designed to target both CD33 and CD3. It consists of two single-chain variable fragments (scFv): one directed against the tumor-associated antigen CD33 on myeloid cells and another against the CD3 antigen on T lymphocytes. By binding these targets simultaneously, emerfetamab redirects cytotoxic T cells to recognize and kill CD33-expressing cancer cells through immunostimulatory and antineoplastic mechanisms. The molecule includes a half-life extension Fc moiety for improved pharmacokinetics. Emerfetamab was originally developed by Amgen and later by BeiGene for the treatment of acute myeloid leukemia[1][2][3][4].
- Other names
- AMG 673AMG673AMG-673Anti-CD33xanti-CD3-BiTEAnti-CD-33xanti-CD3-BiTEAnti-CD 33xanti-CD3-BiTEAnti-CD33xanti-CD3-BiTE-bispecific-T-cell-engagerAnti-CD-33xanti-CD3-BiTE-bispecific-T-cell-engagerAnti-CD 33xanti-CD3-BiTE-bispecific-T-cell-engager
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on emerfetamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emerfetamab.